

RECEIVED
CENTRAL FAX CENTER
JUL 27 2006

AMENDMENT OF THE CLAIMS

Claim Listing:

Claims 1-20 (canceled).

Claim 21 (currently amended). An antibody or antigen-binding fragment thereof which specifically binds to the histamine receptor ~~a polypeptide comprising at least 12 contiguous residues of the amino acid sequence~~ of SEQ ID NO: 2.

Claim 22 (previously presented). The antibody of claim 21 wherein said antibody is a monoclonal antibody.

Claim 23 (previously presented). The antibody of claim 21 wherein said antibody is a polyclonal antibody.

Claim 24 (previously presented). The antibody of claim 21 wherein said antibody is a neutralizing antibody.

Claim 25 (previously presented). The antigen-binding fragment of claim 21 wherein said fragment is selected from the group consisting of a Fab, a Fc, a F(ab)₂, and a Fv fragment.

Claim 26 (previously presented). The antibody or antigen-binding fragment of claim 21 wherein said antibody or fragment further comprises a detectable label.

Claim 27 (previously presented). The antibody or antigen-binding fragment of claim 26 wherein said label is selected from the group consisting of a radiolabel, a fluorescent label, a chemiluminescent label, and an enzymatic label.

Claim 28 (previously presented). An anti-idiotypic antibody which specifically binds to the antibody or antigen-binding fragment of claim 21.

Claims 29-36 (canceled).

Claim 37 (new). A hybridoma comprising the antibody of claim 22.

Claim 38 (new). A phage comprising the antibody of claim 22.

Claim 39 (new). A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of claim 21.

Claim 40 (new). A pharmaceutical composition comprising the antibody of claim 22.

Claim 41 (new). A pharmaceutical composition comprising the antibody of claim 24.

Claim 42 (new). A pharmaceutical composition comprising the antigen-binding fragment of claim 25.